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EDITORIAL
Low molecular weight heparin: does it represent a clinical opportunity
for preventing preeclampisa associated with fetal growth restriction?
Introduction
The Cochrane Collaboration and Blood recently published
two meta-analyses showing that low molecular weight heparin
(LMWH) improved ‘‘outcomes in women at risk of placental
dysfunction’’, and ‘‘may be a promising therapy for recurrent,
severe, placenta-mediated pregnancy complications’’. This
editorial attempts to define which of the many phenotypes of
hypertensive diseases of pregnancy (HDP) might benefit from
such prevention. Shallow trophoblastic invasion, dysfunc-
tional placenta and endothelial damage, associated with fetal
growth restriction, do not match all clinical phenotypes. A
large majority of women suffering from pre-eclampsia give
birth to normal weight babies and placentas. It is very likely
that in these latter cases, endothelial dysfunction, hyperten-
sion and organ damage are mainly caused by maternal factors
that result in the low grade inflammation of normal placentas
at term. However, if prevention is targeted just at placental
pre-eclampsia, then the powerful immunomodulation of
LMWH might play a role. Heparin is not primarily an
antithrombotic peptide: it is parsimoniously released by mast-
cells in sites of tissue injury, with a substantial impact on
inflammation and oxidative stress and displays critical
immunomodulation activities on trophoblast. This explains
why LMWH worked better in trials focused on early severe
HDPs associated with fetal growth restriction. LMWHs
should be considered to prevent the recurrence of placental
pre-eclampsia.
Definition of the target of prevention
A recent publication by ‘‘the Cochrane Collaboration’’ of a
systematic review of 10 randomized trials of fair to good
quality on pregnant patients without thrombophilic conditions
[1] showed that low molecular weight heparin (LMWH)
improved ‘‘maternal or infant health outcomes in women
considered at risk of placental dysfunction’’. Soon after that,
‘‘The Study Group: Low-Molecular-Weight Heparin for
Placenta-Mediated Pregnancy Complications’’ reported simi-
lar conclusions in blood [2]: ‘‘LMWH may be a promising
therapy for recurrent and especially severe, placenta-mediated
pregnancy complications’’.
These evidence-based conclusions differ in their clinical
impact, the first established grounds for the clinical use of
LMWH in women at risk, the second calls for a new series of
well-designed trials. Yet, such research will cause quite a few
people’s heartbeats to race and probably raise many more
eyebrows, depending on the country, the medical school
attended, and individual opinions and beliefs.
It might help to sit back and focus on the definition of
exactly what we are aiming to prevent. A recent paper by
Leslie Myatt, Christopher Redman, Anne Staff et al for the
Global Pregnancy CoLaboratory [3] might help define a way
out of the maze of Hypertensive Diseases of Pregnancy
(HDPs) and make the most of the new scope for prevention, as
reported by these two systematic reviews: ‘‘It is possible that
within the syndrome there may be different phenotypes with
pathogenic pathways that differ between the subtypes. The
capacity to recognize and to exploit different subtypes is of
obvious importance for prediction, prevention, and
treatment’’.
What are we trying to prevent with LMWH? A single
disease, or the whole syndrome? The very sound of the name
‘‘pre-eclampsia’’ conjures up the marvels compiled over the
last twenty years on the critical relationship between the
appendices of the new creature, the trophoblast, and its host
environment, the maternal decidua and uterus [4]. This
background directs us to those pregnancies with abnormal
placental vascular development, fetal growth restriction,
maternal endothelial dysfunction, hypertension and in some
case proteinuria. Yet this picture explains only a fraction of
the causes leading to endothelial dysfunction that have
tentatively been put forward as a common final pathway to
this syndrome [5]. In spite of its solid scientific background,
this sequence of placental, fetal and maternal damage does
not apply to the definition of pre-eclampsia according both to
some of the current guidelines provided by the major
scientific societies [6–9] and by some medical blogs. In
fact, some guidelines include fetal growth restriction in the
very definition of pre-eclampsia [6,7], while others do not
[8,9]. To add to the paradox, in 2014, diagnosis of this
pregnancy complication is still based on the identification of
proteinuria as described in 1840 by Pierre Rayer, a
Frenchman, the first to describe proteinuria in eclamptic
pregnant patients, and later complemented by the introduction
of the Scipione Riva-Rocci’s mercury blood pressure man-
ometer in 1896 that led to the recognition that pre-eclampsia/
eclampsia was a hypertensive disorder.
As a matter of fact, the idea that pre-eclampsia diagnosed
by nineteenth century criteria could be a single disease had
already been challenged [5,10,11] even though this did not
gain general credence and had little impact on clinical
guidelines. The paper by the Global Pregnancy CoLaboratory
group [3] prudently addresses different markers of this
complex syndrome. We recently reviewed this problem [12]
by trying to identify the subset of cases with hypertension and
proteinuria without vascular placental damage and fetal
growth restriction. Every day in labor and delivery rooms
worldwide, two major clinical phenotypes can be observed:
women affected by ‘‘pre-eclampsia’’ or HDPs may deliver
normal weight babies, with normal placentas, most of them
after 34 weeks, but more commonly after 37 weeks of
gestation, sometimes even associated with gestational dia-
betes and big babies. Less frequently, women with a similar
diagnosis of ‘‘pre-eclampsia’’ or HDP deliver growth
restricted fetuses and small placentas regardless of the
gestational age, even if the most severe cases of IUGR
occur before 34 weeks of gestation. Yet, to the great surprise
of external observers, such entirely different conditions still
go under the same name of ‘‘pre-eclampsia, or HDP, and the
same CDI9 number.
Early and late onset pre-eclampsia, or how time
domain criteria ousted physiology from clinical
obstetrics
Attempts have been made to adhere to clinical real life
scenarios by sub-classifying pre-eclampsia into an early onset
form, occurring before 34 weeks of gestation, and a late onset
form occurring after 34 weeks of gestation. We are all aware
of similar attempts to classify diseases based on the time axis.
The distinction between juvenile and adult diabetes as a
possible classification of diabetes survived for a few years
before being replaced by a physio-pathological classification,
yet that vision was based on a large time domain and an
accepted overlapping between the two. Probably for the first
time in western medicine the passage of one single day, from
33 weeks and 6 days to the next day in pregnancy, changes the
name of a disease, with all the consequences in terms of
epidemiology, prediction, prevention, diagnosis and therapy.
Time does not qualify severity as in premature delivery, in the
world of pre-eclampsia, time dictates categories that might
even result in different prognoses or even preventive
strategies.
In spite of this time dependent classification, placental
pathology [13] and the clinical hard facts, fetal and placental
weight, fare better under this definition. The obvious fact is
that endothelial dysfunction due to low grade maternal
inflammation resulting in late pregnancy fetal-placenta TH1
milieu [6] rarely occurs before 34 weeks of gestation and
hence the physio-pathological background of these early onset
cases is more homogeneous. This sub-classification satisfies
some experts in that it provides prevention strategies for early
onset PE but not for late onset cases [14], or vice versa
[15,16]. In fact, the real area of confusion concerns the ‘‘late
onset’’ disease where the epidemiology of maternal meta-
bolic syndrome and its low grade inflammatory vascular
damage differs from country to country [17], and according to
macro-ethnicity, whereby mothers of south American origin,
and of Afro-Caribbean ethnicity proved to have the highest
prevalence of maternal pre-eclampsia delivering normal
weight newborns [18] at term.
The object of prevention: placental pre-eclampsia
associated with fetal growth restriction
The following sentences, quoted successively below, pave the
way for the definition of the object of prevention/help to
define what we are aiming to prevent: ‘‘The diagnosis of pre-
eclampsia using blood pressure and proteinuria is of limited
use because they are tertiary, downstream features of the dis-
ease’’ [19]; ‘‘Poor early placentation is especially associated
with early onset disease. Predisposing cardiovascular or
metabolic risks for endothelial dysfunction, as part of an
exaggerated systemic inflammatory response, might dominate
in the origins of late onset pre-eclampsia’’ [10]; ‘‘. . . a major
cause (of pre-eclampsia) is the failure to develop an adequate
blood supply to the placenta, leading to placental oxidative
stress. This . . . triggers an inflammatory response and endo-
thelial dysfunction. Alternatively, pre-eclampsia can develop
in the presence of a normal placenta in women who
are susceptible to systemic inflammation’’ [5]; ‘‘In
conclusion . . . A growing body of evidence suggests that the
development of early and late pre-eclampsia are two distinct
pathophysiological processes with distinct maternal pheno-
types predisposing to the development of each’’ [20];
‘‘. . . with profoundly reduced placental perfusion . . . almost
any woman would get pre-eclampsia. Conversely, the
woman with extensive predisposing constitutional sensitiv-
ity could develop pre-eclampsia with very little reduced
perfusion’’ [11].
What we wish to discuss in the following chapters is how
to prevent ‘‘placental pre-eclampsia’’ as described by
Steegers [10], and beautifully distinguished from maternal
pre-eclampsia by Borzychowski et al. [5]. The placenta is
obviously also part of the picture in maternal pre-eclampsia,
but does not share the distinct lesions that are typical
consequences of early shallow trophoblastic invasion.
How to diagnose placental pre-eclampsia associated
with fetal growth restriction
This clinical phenotype is not just a hypothetical model, it can
be easily diagnosed and differentiated when maternal high
blood pressure and proteinuria are observed in a pregnant
women. Fetal growth restriction can be determined by
traditional ultrasound biometry. In our recent experiment
that is part of a larger ongoing multicenter observational trial,
23 of 34 consecutive patients delivered with HDP  34 weeks
of gestation gave birth to SGA newborns with a prenatal
diagnosis of growth restricted fetuses (68%), whereas only 56
of 217 patients delivered with HDP434 weeks of gestation
gave birth to growth restricted fetuses (26%) (p50.0001).
Average Body mass index, as a proxy of the risk of metabolic
syndrome and maternogenic endothelial dysfunction was 25.9
in mothers of IUGR fetuses and 30.1 in mothers of AGA
newborns (p50.0001). Fetal growth restriction is a robust,
reproducible, worldwide spread clinical skill that can easily
be applied prenatally to all pregnancies with HDP.
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Like all biological measurements, including blood pres-
sure, ultrasound fetal biometry has its limitations. Yet this is
the most simple, universally available, first-step approach to
defining different HDP phenotype during pregnancy, when
classification is most needed. This is possibly the first
criterion that can be used to differentiate the two main HDP
clinical phenotypes amongst those addressed in depth by
Myatt and co workers [3]. Uterine Doppler velocimetry could
be added to confirm placental vascular insufficiency [3,4,21],
and the severity of placental insufficiency can even be
predicted by arterial umbilical Doppler since Pulsatility Index
[22] proved by and large to be a good proxy for the reduction
of blood flow volume from the placenta to the fetal body [23].
We have recently been able to complement these traditional
biophysical landmarks with biochemical markers [19] that
help to define the severity of the evolution of the maternal
condition among women with poor angiogenic placental
factors. As would be expected from the above, the reported
sensitivity of low PIGF values, a marker strongly associated
with poor vascular placental development, in predicting
delivery within 14 days in pre-eclamptic patients is as high
as 68% in cases delivered before 35+0 weeks, and as low as
22% later on.
Heparin – a potential key player for prevention
In common obstetric medical parlance, heparin is considered
to be a systemic antithrombotic molecule. Heparin is in fact
an ancestral polypeptide, present in the evolutionary scale in
shrimps, mussels, lobsters, whales, turkey, and finally mam-
mals. Heparin bears the highest negative charge among
mammalian polypeptides and its remarkable properties are
safely stored in mast cells [24], while the coagulation balance
is controlled by heparin sulphate proteoglycans produced by
endothelial cells [25]. Heparin is released by mast cells into
small vessels at sites of tissue injury where its main role is
that of a key co-factor in tissue from bacteria and foreign
materials [26].
LMWH: a window of opportunity for
immunomodulation
It is very likely that our knowledge of trophoblast invasion
and its modulation by peripheral Treg, despite the consider-
able amount of data, is insufficient to provide clues for
primary prevention. However, we can probably modulate
the pro-coagulatory effect of inflammation using low dose
aspirin [14], we can try to modulate established tissue
inflammation using LMWHs [1], or reduce inflammation and
oxidative stress, and possibly in the future protect local and
systemic endothelium dysfunction using statins (parvastatin)
[27,28]
There is a growing body of evidence to show that LMWH
plays a role in inflammation by decreasing inflammatory
cytokines [29], leukocyte adhesion to damaged tissues [30],
and by reducing the production of inflammatory cytokines
such as IL8-IL6-IL1b and TNFa and of the NkB factor [31]
by monocytes, and possibly by reducing complementary
activation by similar trophoblastic cells with specific anti-
phospholipids activating properties [32].
Among the controversial questions regarding the role of
LMWHs in human reproduction, there are observations that
consistently prove the role of LMWHs in counteracting the
role of anti-phospholipids by inhibiting endometrial neo-
angiogenesis [33], in stimulating epidermal growth factors in
human throphoblast in the first trimester, and according to
Drewlo et al. [34]: ‘‘lower doses of LMWH, equivalent
to levels that the placental villi would be exposed to in
pregnancy, induce syncytial fusion, hCG secretion and
placental apoptotic turnover’’.
Controversies regarding the possible negative side effects
of LMWHs on syncytial knots through the unwanted release
of soluble factors binding the placental growth factor had
been elucidated by Yagel [35]: in brief, the findings reported
showed that although syncytial knots do indeed release the
blocking soluble factor sFlit-1, they do so together with two
to four times the amount of VEGF, hence establishing a
favorable ratio.
LMWH from bench to trials and bedside
If the research done so far on LMWH is scientifically
consistent, and it is consistent, then its possible application
from bench to bedside in the prevention of placental pre-
eclampsia could be considered.
Criticisms have been levelled against the possible clinical
use of LMWH to prevent the recurrence of ‘‘pre-eclampsia’’.
As a matter of fact, when a variety of abnormal pregnancy
outcomes were included in clinical trials such as in the
HAPPY study [36], no effects were observed from the early
adoption of LMWH prophylaxis. In that study, of 135 patients
recruited over four years in eight centers, only 28 patients had
had a previous growth restricted fetus, while 48 women had
had previous uneventful pregnancies. Furthermore, when such
preventive potential was established in women who had had
previous repeated miscarriages before 14 weeks of gestation,
no therapeutic advantage was observed [37]. An additional
complicating factor had long been the ‘‘translation’’ of
LMWH’s prevalent role as an anti-thrombophilic agent in
clinical hematology into maternal-fetal medicine [38,39],
where immunomodulation is most wanted and expected from
LMWH prophylaxis.
The HAPPY negative findings have been recently
replicated by the TIPPs’ study [40] on a similar background.
Eligibility criteria suffered from the scientific background of
the late nineties, when the study was designed. Thrombophilic
conditions included hetero-zygosity for factor V Leiden and
Prothromobin mutation, as well as first degree relative
with deep vein thrombosis (31% of the cohort). Similarly
‘‘placenta-mediated pregnancy complications’’ included early
pregnancy loss (16% of the cohort), as well as all phenotypes
of preeclampsia (16%) (early, late, severe, non severe).
Overall in a 12 years recruitment, as regards severe placenta
mediated pregnancy complications, only five SGA fetuses5
the 5th percentile and 11 cases of early or severe preeclampsia
were included in this study. Its conclusions are unfortunately
embedded in the discussion and not in the abstract: ‘‘In
summary, higher quality evidence suggests that LMWH does
not prevent recurrent non-severe placenta-mediated preg-
nancy complications, whereas lower quality evidence suggests
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that LMWH might prevent recurrent severe placenta-
mediated pregnancy complications’’.
As a matter of fact, both de Vries and Rey observed
positive results from the adoption of LMWH prophylaxis,
even if the first trial [41] excluded non-thrombophilic patients
with previous early onset PE and the second trial [42]
excluded thrombophilic patients from cases with severe APO
in previous pregnancies. These two studies serve to further
illustrate that the anti-thrombophilic role of LMWH is not the
key feature in placental pre-eclampsia. In our prospective
cohort [43] of pregnant women with previous severe APO
associated with small babies or unexplained fetal death
between 20 and 37 weeks of gestation, LMWH proved to have
a positive effect both in 50 thrombophilic women and in 50
non-thrombophylic women.
The last 10 years of pilot studies [43,44], small trials
[45–47], and finally large trials [48] have built up different
levels of evidence that have, in the final analysis, prompted a
systematic revision of the selected randomized trials [1].
In this recent Cochrane systematic revision [1], despite the
fact that the HAPPY study [36] data had been included with
its burden of non-placental abnormal pregnancy outcomes,
and that the paper by de Vries [41], focusing mainly on cases
of placental insufficiency had been left out, the odds are in
favor, or even strongly in favor, of LMWH proving valuable in
preventing pre-eclampsia, preterm birth before 34 weeks of
gestation and fetal growth restriction below the 10th percent-
ile and other main outcomes. In the meta-analysis reported by
blood [2], the impact on severe or early pre-eclampsia was
measured by a relative risk of 0.16 (C.L. 0,07–0,36), more
than a fourfold reduction of the risk of recurrence. Overall,
these positive findings may result in a change in clinical
attitudes even among ‘‘purists’’ who had consistently rejected
the contribution of LMWH in reducing the risk and severity
of recurrence of abnormal pregnancy outcomes due to
shallow trophoblastic invasion. The additional advantage of
this therapy is its negligible impact in terms of side effects
and unwanted complications [49]
On the basis of the above evidence, it could be of interest
to go back to an important finding reported by our prospective
cohort [43]. Patients had in fact been recruited on the grounds
of the severity of their obstetrical history between 12 and
24 weeks of gestation. One might argue that it is too late to
convey a positive shift with regard to trophoblastic invasion.
As a result of this real life clinical recruitment, the recurrence
of the disease was similar to that reported by cohorts of severe
placental APO, i.e. 25%. The striking result was the marked
reduction in the severity of cases where hypertensive diseases
of pregnancies and fetal growth restriction recurred. In the
obstetrical history of our cohort, 53% of pregnancies were
delivered before 34 weeks of gestation. This was assumed to
represent a robust score of severity in the pregnancy index.
In the treated pregnancies, the percentage of cases delivered
534 weeks of gestation was brought down to 4%.
To explain these findings, we can speculate that the
immunomodulation promoted by LMWH and its impact on
growth factors and apoptosis and upon the overall turnover of
placental cells might and should be deployed throughout
gestation, even if the early and primitive trophoblastic
dysfunction cannot be entirely modified or reversed.
Perspectives
In conclusion, the secondary prevention of a disease requires
that the limits of the disease itself be clearly defined. It is very
likely that placental pre-eclampsia associated with fetal growth
restriction should be considered separately from maternal
pre-eclampsia with normally grown fetuses [50]. LMWH
might then play a role in preventing the recurrence of placental
pre-eclampsia or more widely in hypertensive diseases of
pregnancy associated with fetal growth restriction at any
gestational age of onset. This role derives by and large from
the core biological immunomodulation activity of LMWH.
There is now evidence, in accordance with the principles
of evidence-based medicine, that LMWH helps reduce the
recurrence and severity of placental pre-eclampsia, and in our
opinion there is no reason to deprive patients who could
benefit from this secondary prevention of this opportunity.
In our opinion, the next step is to start to study the possible
role of LMWH in first-time patients suffering from HDP with
fetal growth restriction, and possibly design strict randomized
trials on preventing placental pre-eclampsia in first-time
mothers who tested positive in the first and second trimesters
when screening for placental insufficiency. Statins or not, it
would be a pity if the potential benefits of LMWHs were not
properly investigated just on the basis of opinions that
sometimes seem to be more rooted in personal credence
rather than scientific grounds.
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